^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    leucovorin calcium

    Company:
    Generic mfg.
    Drug class:
    Folate analog
    Related drugs:
    2d
    ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases (clinicaltrials.gov)
    P2, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    2d
    LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation (clinicaltrials.gov)
    P1/2, N=99, Not yet recruiting, Luye Pharma Group Ltd.
    New P1/2 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium
    2d
    Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=35, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    3d
    Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU (clinicaltrials.gov)
    P2, N=583, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    3d
    SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, University of Miami | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    3d
    PANACHE01-PRODIGE48 Study: Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=153, Completed, University Hospital, Rouen | Unknown status --> Completed
    Trial completion
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    3d
    RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=28, Completed, Canadian Cancer Trials Group | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306) • camonsertib (RP-3500)
    3d
    Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy. (PubMed, ESMO Gastrointest Oncol)
    Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX) therapies are widely used to treat advanced pancreatic ductal adenocarcinoma (PDAC)...In Japanese real-world data, GnP showed superior TTP compared with FFX for advanced PDAC. TP53 status may serve as a prognostic biomarker in patients receiving GnP therapy.
    Journal • HEOR • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation • TP53 wild-type
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    3d
    Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany. (PubMed, ESMO Gastrointest Oncol)
    Liposomal irinotecan in combination with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) is the only approved therapy for metastatic PAC following gemcitabine-based therapy, based on the survival benefit demonstrated in the phase III NAPOLI-1 trial. Factors such as patient age and number of previous lines of treatment that were not identified in the NAPOLI-1 nomogram may be associated with long-term survival with nal-IRI+5-FU/LV in the real-world. In conclusion, this review has shown that while prognostic factors are useful for patient stratification, their predictive value on the efficacy of nal-IRI+5-FU/LV is low, thus this treatment may also result in long-term survival in patients with apparently unfavorable characteristics.
    Review • Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    3d
    Intensified Chemotherapy in CRC After Resection of Liver Metastases (clinicaltrials.gov)
    P2/3, N=124, Completed, Institut du Cancer de Montpellier - Val d'Aurelle | Phase classification: P3 --> P2/3
    Phase classification
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    3d
    Protective Effect of N-Acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=46, Completed, Tanta University
    New trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    4d
    BBOpCo: Botensilimab and Balstilimab Optimization in Colorectal Cancer (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Nicholas DeVito, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)